ArticleOncoimmunology
Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 26 citations in OpenAlex.
- Oncolytic viruses and cytokine-based gene therapies reprogram the tumor microenvironment.Nature cancer · 2026Review
- From infection to tumor: genetic evidence of viral antibody immune response' role in urologic cancer development.Discover oncology · 2025Article
- Research progress on recombinant NDV in cancer therapy.Frontiers in immunology · 2025Review
- Oncolytic vaccinia virus armed with anti-CD47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunity.Journal for immunotherapy of cancer · 2024Article
- Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II presentation of this tumor antigen by melanoma and dendritic cells.Cancer immunology, immunotherapy : CII · 2023Article
- Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy.Cancer gene therapy · 2022Review
- Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction.Cancer cell international · 2022Review
- IL-36γ-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunity.Cancer immunology, immunotherapy : CII · 2021Article
- Delivery of cancer therapies by synthetic and bio-inspired nanovectors.Molecular cancer · 2021Review
- Cancer Vaccines: Antigen Selection Strategy.Vaccines · 2021Review
- Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs.Current oncology (Toronto, Ont.) · 2020Review
- Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma.Leukemia · 2020Article
- High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma.Molecular therapy oncolytics · 2020Article
- Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy.Journal of translational medicine · 2020Review
- oHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity.Molecular therapy oncolytics · 2020Article
- Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology.Oncoimmunology · 2020Review
- The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism.Molecular therapy oncolytics · 2019Article
- Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy.Biomedicines · 2019Review
- Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.EBioMedicine · 2018Review
- Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend.Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 11 institutions in 7 countries.
Funding
Abstract
Oncolytic immunotherapy using oncolytic viruses (OV) has been shown to stimulate the antitumor immune response by inducing the release of tumor-associated antigens (TAA) and danger signals from the dying infected tumor cells. In this study, we sought to determine if the lysis of tumor cells induced by different OV: measles virus, vaccinia virus, vesicular stomatitis virus, herpes simplex type I virus, adenovirus or enterovirus, has consequences on the capacity of tumor cells to present TAA, such as NY-ESO-1. We show that the co-culture of NY-ESO-1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.